Marker Therapeutics Inc (MRKR)

[microcapbiotech]

8-K filed.
On November 17, 2023, Marker Therapeutics, Inc. (the “Company”) delivered a notice of termination (the “Notice”) to Danforth Advisors, LLC (“Danforth”) terminating the consulting agreement (the “Danforth Consulting Agreement”) by and between the Company and Danforth, dated June 6, 2023, pursuant to which, among other things, Eliot M. Lurier was appointed as the Company’s Interim Chief Financial Officer. Pursuant to the Notice, the Danforth Consulting Agreement will terminate on January 16, 2024.
On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer and Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer. The biographical data and related-person transactions disclosures for Dr. Vera, as set forth in the Company’s definitive proxy statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on April 28, 2023, are incorporated herein by reference.